BioLineRx Historical Income Statement

BLRX Stock

USD 0.32 0.23 41.82%

Historical analysis of BioLineRx income statement accounts such as Interest Expense of 2.3 M, Selling General Administrative of 17.5 M or Selling And Marketing Expenses of 15.3 M can show how well BioLineRx performed in making a profits. Evaluating BioLineRx income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioLineRx's future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining BioLineRx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioLineRx is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.

About BioLineRx Income Statement Analysis

BioLineRx Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioLineRx shareholders. The income statement also shows BioLineRx investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

BioLineRx Income Statement Chart

At this time, BioLineRx's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 2.3 M in 2024, whereas Total Revenue is likely to drop slightly above 4.6 M in 2024.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Research Development Ebitda Income Before Tax

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioLineRx. It is also known as BioLineRx overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on BioLineRx income statement and is an important metric when analyzing BioLineRx profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Most accounts from BioLineRx's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioLineRx current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy BioLineRx Stock please use our How to Invest in BioLineRx guide.At this time, BioLineRx's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 2.3 M in 2024, whereas Total Revenue is likely to drop slightly above 4.6 M in 2024.

BioLineRx income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.68	0.54	0.54	-0.13	-0.14	0.54	-0.44	-0.48	0.04	-0.45	-0.05	0.4	-0.36	-0.15	-0.59	0.53	-0.58	0.22	-0.56	0.64
Interest Expense	0.68		0.63	0.69	-0.34	-0.37	0.69	-0.72	-0.71	0.26	-0.7	-0.17	0.61	-0.37	0.02	-0.7	0.06	-0.74	0.04	-0.78	0.79
Selling General Administrative	0.54	0.63		0.98	-0.21	-0.22	0.95	-0.8	-0.85	-0.05	-0.84	-0.11	0.69	-0.62	-0.25	-0.87	0.18	-0.94	0.5	-0.15	0.72
Selling And Marketing Expenses	0.54	0.69	0.98		-0.23	-0.24	0.93	-0.81	-0.84	-0.06	-0.84	-0.13	0.7	-0.61	-0.23	-0.83	0.03	-0.91	0.47	-0.21	0.69
Total Revenue	-0.13	-0.34	-0.21	-0.23		0.99	-0.27	0.27	0.25	-0.23	0.25	0.94	-0.28	0.35	0.28	0.24	0.11	0.29	0.42	0.34	-0.35
Gross Profit	-0.14	-0.37	-0.22	-0.24	0.99		-0.27	0.25	0.24	-0.19	0.23	0.88	-0.27	0.25	0.16	0.22	0.11	0.29	0.38	0.33	-0.35
Other Operating Expenses	0.54	0.69	0.95	0.93	-0.27	-0.27		-0.78	-0.82	0.23	-0.82	-0.19	0.78	-0.68	-0.34	-0.84	0.24	-0.95	0.37	-0.29	0.76
Operating Income	-0.44	-0.72	-0.8	-0.81	0.27	0.25	-0.78		0.99	-0.25	0.99	0.21	-0.74	0.7	0.25	0.95	0.0	0.87	-0.13	0.37	-0.76
Ebit	-0.48	-0.71	-0.85	-0.84	0.25	0.24	-0.82	0.99		-0.21	1.0	0.18	-0.75	0.69	0.23	0.96	-0.08	0.91	-0.18	0.35	-0.78
Research Development	0.04	0.26	-0.05	-0.06	-0.23	-0.19	0.23	-0.25	-0.21		-0.21	-0.29	0.27	-0.35	-0.31	-0.19	0.23	-0.19	-0.5	-0.47	0.23
Ebitda	-0.45	-0.7	-0.84	-0.84	0.25	0.23	-0.82	0.99	1.0	-0.21		0.18	-0.75	0.69	0.23	0.96	-0.06	0.9	-0.17	0.33	-0.76
Cost Of Revenue	-0.05	-0.17	-0.11	-0.13	0.94	0.88	-0.19	0.21	0.18	-0.29	0.18		-0.25	0.51	0.55	0.16	0.1	0.19	0.49	0.31	-0.27
Total Operating Expenses	0.4	0.61	0.69	0.7	-0.28	-0.27	0.78	-0.74	-0.75	0.27	-0.75	-0.25		-0.64	-0.33	-0.73	0.15	-0.8	0.1	-0.37	0.85
Income Before Tax	-0.36	-0.37	-0.62	-0.61	0.35	0.25	-0.68	0.7	0.69	-0.35	0.69	0.51	-0.64		0.86	0.71	-0.19	0.68	0.03	0.34	-0.62
Total Other Income Expense Net	-0.15	0.02	-0.25	-0.23	0.28	0.16	-0.34	0.25	0.23	-0.31	0.23	0.55	-0.33	0.86		0.28	-0.19	0.27	0.14	0.19	-0.28
Net Income	-0.59	-0.7	-0.87	-0.83	0.24	0.22	-0.84	0.95	0.96	-0.19	0.96	0.16	-0.73	0.71	0.28		-0.27	0.95	-0.2	0.37	-0.84
Income Tax Expense	0.53	0.06	0.18	0.03	0.11	0.11	0.24	0.0	-0.08	0.23	-0.06	0.1	0.15	-0.19	-0.19	-0.27		-0.29	0.0	-0.17	0.35
Net Income From Continuing Ops	-0.58	-0.74	-0.94	-0.91	0.29	0.29	-0.95	0.87	0.91	-0.19	0.9	0.19	-0.8	0.68	0.27	0.95	-0.29		-0.27	0.36	-0.85
Interest Income	0.22	0.04	0.5	0.47	0.42	0.38	0.37	-0.13	-0.18	-0.5	-0.17	0.49	0.1	0.03	0.14	-0.2	0.0	-0.27		0.42	0.06
Net Interest Income	-0.56	-0.78	-0.15	-0.21	0.34	0.33	-0.29	0.37	0.35	-0.47	0.33	0.31	-0.37	0.34	0.19	0.37	-0.17	0.36	0.42		-0.62
Reconciled Depreciation	0.64	0.79	0.72	0.69	-0.35	-0.35	0.76	-0.76	-0.78	0.23	-0.76	-0.27	0.85	-0.62	-0.28	-0.84	0.35	-0.85	0.06	-0.62

Click cells to compare fundamentals

BioLineRx Account Relationship Matchups

BioLineRx income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.2M	934K	702K	654K	1.4M	1.5M
Interest Expense	1.8M	1.5M	984K	2.2M	2.2M	2.3M
Selling General Administrative	3.7M	3.8M	4.3M	5.1M	16.6M	17.5M
Selling And Marketing Expenses	1.4M	857K	840K	6.5M	14.6M	15.3M
Gross Profit	(940K)	(934K)	(702K)	(654K)	1.1M	1.1M
Other Operating Expenses	28.1M	22.9M	24.8M	29.2M	54.5M	57.2M
Operating Income	(28.1M)	(22.9M)	(24.8M)	(29.2M)	(49.7M)	(47.2M)
Ebit	(28.1M)	(22.9M)	(26.0M)	(29.2M)	(58.4M)	(55.5M)
Research Development	23.4M	18.2M	19.5M	17.6M	12.5M	17.3M
Ebitda	(26.9M)	(22.0M)	(25.3M)	(28.5M)	(57.1M)	(54.2M)
Cost Of Revenue	940K	934K	702K	654K	3.7M	4.4M
Total Operating Expenses	28.1M	22.9M	24.8M	29.2M	50.8M	26.0M
Income Before Tax	(25.4M)	(30.0M)	(27.1M)	(25.0M)	(60.6M)	(57.6M)
Total Other Income Expense Net	2.7M	(7.1M)	(2.3M)	4.2M	(10.9M)	(10.4M)
Net Income Applicable To Common Shares	(23.0M)	(25.4M)	(30.0M)	(27.1M)	(24.3M)	(25.6M)
Net Income	(26.8M)	(30.9M)	(28.1M)	(18.9M)	(60.6M)	(57.6M)
Income Tax Expense	1.4M	911K	1.1M	(6.1M)	1K	1.1K
Net Income From Continuing Ops	(25.4M)	(30.0M)	(27.1M)	(25.0M)	(60.6M)	(57.6M)
Interest Income	777K	236K	559K	694K	2.0M	2.1M
Net Interest Income	(1.1M)	(1.3M)	(447K)	(1.1M)	(162K)	(170.1K)
Reconciled Depreciation	940K	934K	703K	654K	1.4M	886.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BioLineRx Stock Analysis

When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioLineRx Historical Income Statement

About BioLineRx Income Statement Analysis

BioLineRx Income Statement Chart

Other Operating Expenses

Income Before Tax

BioLineRx income statement Correlations

BioLineRx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioLineRx income statement Accounts

Also Currently Popular

Additional Tools for BioLineRx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Gross Profit	+ 0.99	Total Revenue
Ebit	+ 0.99	Operating Income
Ebitda	+ 0.99	Operating Income
Selling And Marketing Expenses	+ 0.98	Selling General Administrative
Net Income	+ 0.96	Ebit

Net Income From Continuing Ops	- 0.95	Other Operating Expenses
Net Income From Continuing Ops	- 0.94	Selling General Administrative
Net Income From Continuing Ops	- 0.91	Selling And Marketing Expenses
Net Income	- 0.87	Selling General Administrative
Reconciled Depreciation	- 0.85	Net Income From Continuing Ops
Ebit	- 0.85	Selling General Administrative